MRNA therapy takes on rare hormone disorder
NCT ID NCT07530705
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an mRNA drug called XH-02 in 15 adults with hypoparathyroidism, a condition where the body doesn't make enough parathyroid hormone. The drug is injected under the skin to help replace the missing hormone and control calcium levels. The main goal is to check safety, but researchers will also measure how well it restores hormone and mineral balance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily shot free teens from calcium pills?
- Weekly shot could free hypoparathyroidism patients from daily pills
- New daily shot could ease rare hormone disorder
- Glowing goggles could prevent calcium crash after thyroid surgery
- MRNA therapy offers hope for rare hormone disorder
- Pump delivery of hormone may steady calcium levels in rare disorder